Tebipenem HBr (tebipenem pivoxil hydrobromide)
Complicated Urinary Tract Infection (cUTI), including pyelonephritis
Phase 3PIVOT-PO trial met primary endpoint and stopped early for efficacy (May 2025)
Key Facts
Indication
Complicated Urinary Tract Infection (cUTI), including pyelonephritis
Phase
Phase 3
Status
PIVOT-PO trial met primary endpoint and stopped early for efficacy (May 2025)
Company
About Spero Therapeutics
Founded in 2013, Spero Therapeutics is dedicated to pioneering differentiated medicines for patients with rare diseases and serious bacterial infections, particularly addressing the global crisis of antibiotic resistance. Its most advanced program, tebipenem HBr, achieved a pivotal milestone in May 2025 with the Phase 3 PIVOT-PO trial stopping early for efficacy in cUTI. The company operates with a partnership-centric model, collaborating with government agencies, academic institutions, and pharmaceutical companies to maximize the impact of its innovative therapies.
View full company profile